Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-29
2005-03-29
Huang, Evelyn Mei (Department: 1625)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S230500, C514S337000, C514S314000, C514S443000, C514S275000, C514S259500, C514S249000, C514S243000, C514S248000, C514S367000, C514S394000, C514S303000, C514S301000, C544S105000, C544S183000, C544S236000, C544S279000, C544S331000, C544S350000, C546S122000, C546S113000, C546S114000, C546S118000, C546S174000, C546S281100, C548S159000, C548S194000, C548S305100, C549S051000, C549S057000, C549S058000
Reexamination Certificate
active
06872730
ABSTRACT:
The present invention relates to novel substituted benzofurans and benzothiophenes compounds that are antagonists of alpha V (αv) integrins, for example αvβ3and αvβ5integrins, their pharmaceutically acceptable salts, and pharmaceutical compositions thereof. The compounds may be used in the treatment of pathological conditions mediated by αvβ3and αvβ5integrins, including such conditions as tumor growth, metastasis, restenosis, osteoporosis, inflammation, macular degeneration, diabetic retinopathy, and rheumatoid arthritis. The compounds have the general formula I:where R1, R2, R3, R4, R5, R6, R7, R8, R9, R10, R11, R12, R13, R14, m, n, i, j and k are defined herein.
REFERENCES:
patent: 5223517 (1993-06-01), Muller et al.
patent: 5290788 (1994-03-01), Stevens et al.
patent: 5741796 (1998-04-01), Hartman et al.
patent: 5744488 (1998-04-01), Cross et al.
patent: 6066648 (2000-05-01), Duggan et al.
patent: 6184238 (2001-02-01), Takano et al.
patent: 0 623 607 (1994-11-01), None
patent: WO 9706791 (1997-02-01), None
patent: WO 9723451 (1997-07-01), None
patent: WO 9736859 (1997-10-01), None
patent: WO 9745137 (1997-12-01), None
patent: WO 9800395 (1998-01-01), None
patent: WO 9930713 (1999-06-01), None
patent: WO 0002874 (2000-01-01), None
patent: WO 0033838 (2000-06-01), None
patent: WO 0038719 (2000-07-01), None
patent: WO 0158893 (2001-08-01), None
Batt et al., J. Med. Chem. 2000, 43:41-58.*
Albelda, S.M. “Biology of Disease. Role of Integrins and Other Cell Adhesion Molecules in Tumor Progression and Metastasis,”Lab. Invest. 68:4-17, The United States and Canadian Academy of Pathology, Inc. (1993).
Albelda, S.M., et al., “Integrin Distribution in Malignant Melanoma: Association of the β3Subunit with Tumor Progression,”Cancer Res. 50:6757-6764, American Association for Cancer Research (1990).
Boudreau, N., and Rabinovitch M., “Developmentally Regulated Changes in Extracellular Matrix in Endothelial and Smooth Muscle Cells in the Ductus Arteriosus May be Related to Intimal Proliferation,”Lab. Invest. 64:187-199, The United States and Canadian Academy of Pathology, Inc. (1991).
Brocke, S., et al., “Antibodies to CD44 and integrin α4, but not L-selectin, prevent central nervous system inflammation and experimental encephalomyelitis by blocking secondary leukocyte recruitment,”Proc. Natl. Acad. Sci. USA 96:6896-6901, The National Academy of Sciences (1999).
Brooks, P.C., et al., “Integrin ανβ3Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels,”Cell 79:1157-1164, Cell Press (1994).
Brooks, P.C., “Integrin ανβ3: A Therapeutic Target,”DN&P 10:456-461, Prous Science (1997).
Brooks, P.C., et al., “Antiintegrin ανβ3 blocks human breast cancer growth and angiogenesis in human skin,”J. Clin. Invest. 96:1815-1822, The American Society for Clinical Investigation, Inc. (1995).
Brooks, P.C., et al., “Requirement of Vascular Integrin ανβ3for Angiogenesis,”Science 265:569-571, American Association for the Advancement of Science (1994).
Brooks, P.C., “Cell Adhesion molecules in angiogenesis,”Cancer Met. Rev. 15:187-194, Kluwer Academic Publishers (1996).
Chemical Abstracts English language summary of WO 98/00395 (Document AP1), CAPLUS Accession No. 1998:38464.
Cheresh, D.A., “Structure, function and biological properties of integrin of ανβ3on human melanoma cells,”Cancer Met. Rev. 10:3-10, Kluwer Academic Publishers (1991).
Choi, E.T., et al., “Inhibition of neointimal hyperplasia by blocking ανβ3integrin with a small peptide antagonistGpenGRGDSPCA,” J. Vasc. Surg. 19:125-134, Mosby-Year Book (1994).
Dennis, M.S., et al., “Binding Interactions of Kistrin With Platelet Glycoprotein IIb-IIIa: Analysis by Site-Directed Mutagenesis,”Proteins 15:312-321, Wiley-Liss (1993).
Dialog File 351, Accession No. 14058279, Derwent WPI English language abstract for WO 01/58893 (Document AN2).
Enenstein, J., and Kramer, R.H., “Confocal Microscopic Analysis of Integrin Expression on the Microvasculature and its Sprouts in the Neonatal Foreskin,”J. Invest. Dermatol. 103:381-386, The Society for Investigative Dermatology, Inc. (1994).
Fisher, J.E., et al., “Inhibition of Osteoclastic Bone Resorption In Vivo by Echistatin, an “Arginyl-Glycyl-Aspartyl” (RGD)-Containing Protein,”Endocrinology 132:1411-1413, The Endocrine Society (1993).
Friedlander, M., et al., “Definition of Two Angiogenic Pathways by Distinct ανIntegrins,”Science 270:1500-1502, American Association for the Advancement of Science (1995).
Gladson, C.L., “Expression of Integrin ανβ3 in Small Blood Vessels of Glioblastoma Tumors,”J. Neuropathol. Exp. Neurol. 55:1143-1149, The American Association of Neuropathologists (1996).
Greene, T.W., and Wuts, P.G.M., “Special -NH Protective Groups. Protection for the Amino Group: Special -NH Protective Groups,” inProtective Groups in Organic Synthesis,2nd edition, John Wiley, and Sons, Inc. New York, pp. 267-287 and p. 331 (1991).
Greenspoon, N., et al., “Structural Analysis of Integrin Recognition and the Inhibition of Integrin-Mediated Cell Functions by Novel Nonpeptidic Surrogates of the Arg-Gly-Asp Sequence,”Biochemistry 32:1001-1008, The American Chemical Society (1993).
Hardan, I., et al., “Inhibition of Metastatic Cell Colonization in Murine Lungs and Tumor-Induced Morbidity by Non-Peptidic Arg-Gly-Asp Mimetics,”Int. J. Cancer 55:1023-1028, Wiley-Liss, Inc. (1993).
Hershkovits, R., et al., “Inhibition of CD4+T lymphocyte binding to fibronectin and immune-cell accumulation in inflammatory sites by non-peptidic mimetics of Arg-Gly-Asp,”Clin. Exp. Immunol. 95:270-276, Blackwell Scientific Publishers (1994).
Horton, M., “Current Status Review. Vitronectin receptor: tissue specific expression or adaption to culture?”Int. J. Exp. Pathol. 71:741-759, Blackwell Scientific Publications (1990).
Hynes, R.O., “Integrins: Versatility, Modulation, and Signaling in Cell Adhesion,”Cell 69:11-25, Cell Press (1992).
Juliano, R., “Signal transduction by integrins and its role in the regulation of tumor growth,”Cancer Met. Rev. 13:25-30, Kluwer Academic Publishers (1994).
Kaul, D.K., et al., “Monoclonal antibodies to ανβ3 (7E3 and LM609) inhibit sickle red blood cell-endothelium interactions induced by platelet-activating factor,”Blood 95:368-374, The American Society of Hematology (Jan. 2000).
Ku, T.W., et al., “Direct Design of a Potent Non-Peptide Fibrinogen Receptor Antagonist Based on the Structure and Conformation of a Highly Constrained Cyclic RGD Peptide,”J. Amer. Chem. Soc. 115:8861-8862, The American Chemical Society (1993).
Marquardt, D.W., “An Algorithm for Least-Squares Estimation of Nonlinear Parameters,”J. Soc. Indust. Appl. Math. 11:431-441, Society for Industrial and Applied Mathematics (1963).
Mitsunobu, O., “The Use of Dithyl Azodicarboxylate and Triphenylphosphine in Synthesis and Transformation of Natural Products,”Synthesis 1:1-28, Georg Thieme Verlag (1981).
Nicosia, R.F., and Madri, J.A., “The Microvascular Extracellular Matrix. Developmental Changes During Angiogenesis in the Aortic Ring-Plasma Clot Model,”Amer. J. Pathol. 128:78-90, American Association of Pathologists (1987).
Niiya, K., et al., “Increased Surface Expression of the Membrane Glycoprotein IIb/IIIa Complex Induced by Platelet Activation. Relationship to the Binding of Fibrinogen and Platelet Aggregation,”Blood 70:475-483, Grune & Stratton, Inc. (1987).
Nip, J., et al., “Coordination Expression of the Vitronectin Receptor and the Urokinase-type Plasminogen Act
Anaclerio Beth M.
Marder Victor J.
Marugan Sanchez Juan J.
Tomczuk Bruce E.
U'Prichard David C.
3-Dimensional Pharmaceuticals Inc.
Huang Evelyn Mei
Woodcock & Washburn LLP
LandOfFree
Substituted benzofurans and benzothiophenes, methods of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted benzofurans and benzothiophenes, methods of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted benzofurans and benzothiophenes, methods of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3373578